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Analogues of neuropeptide Y (NPY) containing small N- and C-terminal segments linked via flexible spacer arms were 
found to exhibit receptor binding affinity constants almost as high as NPY as well as post- and presynaptic NPY-agonistic 
activities. One of the most active analogues contains N-terminal NPY segment 14 linked via e-aminocaproic acid (Aca) 
to the C-terminal partially a-helical peptide amide segment 25-36. NPY 14Aca-25-36 is the first highly potent NPY 
agonist, which is of considerably reduced size in comparison to the native hormone. The analogues are accessible by 
solid-phase synthesis using Fmoc strategy. 
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1. INTRODUCTION 
Neuropeptide Y (NPY) [1,2], a linear 36-amino- 
acid peptide amide, is one of the most potent en- 
dogenous vasoconstrictors. NPY is reported to be 
an important neurotransmitter/neuromodulator in 
the regulation of cardiovascular functions [3] and 
may be involved in the pathophysiology of 
hypertension [4,5] which needs clarification by 
specific NPY antagonists. Therefore, we wished to 
evaluate structure-activity relationships on NPY. 
Earlier binding studies [6-111 using synthetic 
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segments of NPY like NPY 19-36 revealed that the 
C-terminal part including the tyrosine amide is 
most relevant for its biological activity. Further 
truncation of this sequence leads to reduced recep- 
tor binding and biological activity [6,7,10,11]. 
2. MATERIALS AND METHODS 
2.1. Synthesis of NPY analogue I-4-Aca-25-36 
The 17-peptide amide was synthesized via the Fmoc strategy 
starting with 4-(Fmoc-aminomethyl)-3,Sdimethoxyphenoxy- 
valeric acid (Fmoc-ADPV) as amide anchor [12] bound to 
alanyl-benzhydrilamine-polystyrene-l % divinylbenzene (0.5 
mmol/g). The protecting groups for side-chain functions were 
Arg(Mtr), His(Trt), Tyr(tBu), Thr(tBu), Ser(tBu) and Lys(Boc). 
Double couplings using firstly I-hydroxybenzotriazol (HOBt) 
and diisopropylcarbodiimide in dimethylformamide and 
secondly symmetric anhydrides in N-methylpyrrolidone were 
carried out on a 430A peptide synthesizer (Applied Biosystems): 
activation time 30 min, coupling time 60 min each, for Thr, Be, 
Tyr and Aca 90 min. Fmoc-Asn-OH was coupled twice as the 
HOBt ester in dimethylformamide and Fmoc-Gin-OH as p- 
nitrophenyl ester in N-methylpyrrohdone (activation time 
10 min). Between the two couplings a wash step with N- 
ethylmorpholine in N-methylpyrrohdone was carried out. Cap- 
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ping was performed with acetic anhydride and N-ethylmor- 
pholine. The resin was washed with N-methylpyrrolidone, 
dichloromethane, methanol and 2-propanol. Fmoc groups were 
removed in piperidine/dimethylformamide (1: 3) within 2 x 
10 min. The final peptide amide was split off in trifluoroacetic 
acid containing thioanisole and 2-methylthiophenol within 4 h 
in 90-95% yield. Complete removal of the Mtr blocking group 
required an additional acidic treatment of the peptide amide at 
50°C for 30 min [13]. 
The peptide was purified on Sephadex G-25 in 5% acetic acid 
followed by preparative RP-HPLC. Amino acid analyses and 
the racemization test of total hydrolyzates were carried out by 
ion-exchange chromatography and by gas chromatography of 
pentafluoropropionylamino acid methyl esters on the chiral sta- 
tionary phase Chirasil-Val. The peptide amide was tested for 
resistance against carboxypeptidase Y. Furthermore, FAB-MS, 
“C NMR, CD and sequencing positions l-4 on the peptide se- 
quencer 477 (Applied Biosystems) were used for characterising 
the NPY agonist. 
2.2. Analytical data of NPY I-4-Aca-25-36 
HPLC column: Nucleosil C18, 5 pm; eluant: A, water/TFA 
(1OO:O.l); B, acetonitrile/TFA (1OO:O.l); flow rate, 1 ml/min; 
gradient, 15-60% B within 30 min; product was eluted after 
22.3 min. 
Amino acid analysis (talc.) [racemization, % uncorr.]: R 3.0 
(3) [l.l], N 1.07 (1) 13.41, T 1.04 (1) [O.l], Q 0.99 (1) [1.8], L 
0.93 (1) [2.7], I 1.91 (2) [1.8], H 1.07 (1) [2.4], Y 2.72 (3) (1.51, 
P 0.82 (1) [2.4], S 0.86 (1) [3.2], K 0.85 (1) [0.98]. 
FAB-MS (M + 1): 2239 mu. Sequencing of the N-terminus 
(PTH derivative yields in pmol/cycle): 1, Y (575); 2, P (444); 3, 
S (157); 4, K (108); 5, cycle no PTH-amino acid, end of Edman 
degradation due to spacer amino acid Aca. 
2.3.3. Receptor binding studies 
Receptor binding studies were performed according to Chang 
et al. [16] with minor modification. Adult male white New 
Zealand rabbits were killed by intravenous injection of pen- 
tobarbitone via an ear vein, the kidneys rapidly removed and 
the cortex dissected. Tissue was homogenized in 50 vols ice-cold 
Tris-HCl (pH 7.4 at 37°C) with a polytron and centrifuged at 
50000 x g for 10 min. Pellets were washed in 50 vols buffer and 
incubated for 40 min at room temperature. The membranes 
were then centrifuged and washed twice. The resulting mem- 
branes were resuspended in 125 vols of the above Tris-HCl buf- 
fer containing 5 mM MgClz, 0.1 mg/ml soybean trypsin 
inhibitor, O.llrlo serum albumin and 0.25 mg/ml of bacitracin. 
For binding studies 230~1 of membrane solution containing 
about 100 pg protein were added to 10 pl buffer (for total bin- 
ding) or 0.3 ,uM (final concentration) unlabeled NPY (for 
nonspecific binding) or the displacer each containing 10 rl tZsI- 
NPY (Amersham Buchler, Braunschweig). After incubation at 
21°C for 90 min the reaction was terminated by filtration under 
reduced pressure with Whatman GF-C glass filters (previously 
soaked for at least 2 h in 1% polyethyleneimine to reduce 
binding to filters) followed by three 3-ml washes with ice-cold 
buffer. Specific binding was calculated as the difference in 
radioactivity bound in the presence and absence of 1.0 pM 
NPY. The equilibrium-dissociation constant (&) of the 
receptor-‘*sl-NPY complex and the maximal number of specific 
binding sites (Bmax) were calculated using the program 
LIGAND [17]. Half-maximal inhibition of the specific binding 
of the ‘r51-NPY is given as the 1Cs0 value. 
3. RESULTS AND DISCUSSION 
A hypothetical 3D structure of NPY 1101 has 
been deduced from the X-ray structure- of the 
homologous avian pancreatic polypeptide APP 
[181. NPY was modelled by exchange of side 
chains of differentiating amino acids followed by 
minimization using force field calculations and 
confirmed by molecular dynamics calculations 
(Discover, Biosym Technologies) (fig. 1). Residues 
1-8 form a type II polyproline helix and residues 
15-32 an amphiphilic a-helix. Experimental proof 
for the a-helical conformation was obtained from 
CD data of various C-terminal segments [l I]. The 
amphiphilic a-helix may be stabilized by 
hydrophobic interactions with the tvne II 
2.3. Biological assays 
2.3.1. Postsynaptic activity 
The blood pressure increasing potency of NPY or NPY 
analoaues was tested in pithed rats. Male rats (Chbb, THGM; 
270-300 g) were anaesthetized with 60 mg sodium pentobar- 
bital i.p., artificially respirated and pithed according to 
Gillespie and Muir [14]. For blood pressure measurement a
carotid artery was cannulated and connected to a Statham 
pressure transducer coupled to a Watanabe Multicorder. A 
catheter for injection of test compounds was placed in a jugular 
vein. Dose-response curves for the pressure responses to NPY 
or NPY analogues were established and ED30 values (dose 
which increased blood pressure by 30 mmHg) were calculated. 
At least three animals were used for each test compound. 
2.3.2. Presynaptic activity 
Presynaptic activity (suppression of noradrenaline release) of 
NPY or NPY analogues was estimated in rat vas deferens 
preparations [15]. Seminal ducts were fixed in an organ bath 
(50 ml modified Krebs solution, 33”C), mounted to force 
display transducer and contracted repeatedly by means of elec- 
trical field stimulation (15 V, 1 ms duration, 0.15 Hz). 
Concentration-response curves for the inhibitory effects of 
NPY and NPY analogues were established and 1% values 
(concentration which inhibits the contraction by 50%) were 
calculated. At least two vas deferens preparations were used for 
one compound. 
pblyproline helix. 
__ 
Based on the hypothetical 3D structure we 
designed an NPY analogue consisting of the 
segments l-4 and 25-36 covalently linked by a 
flexible spacer residue c-aminocaproic acid (fig.]). 
The resulting NPY I-4-Aca-25-36 comprises less 
than half of the amino acid residues of NPY. Sur- 
prisingly, this compound exhibits almost the same 
receptor binding affinity as NPY (table 1). Testing 
120 
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Fig.1. Simulated 3D structure of NPY (lower), and analogue 
NPY l-4-Aca-25-36 (H-YPSK-Aca-RHYINLITRQRY-NH*) 
(upper). In NPY the N-terminal polyproline type II helix 
comprises segment l-8 and the C-terminal a-helix extends from 
position 14 to 32. The dashed line in the NPY structure 
indicates the short-cut made for the design of the analogue 
omitting the icosapeptide segment 5-24. 
revealed that NPY l-4-Aca-25-36 is-a highly po- 
tent NPY agonist. 
Similar receptor affinities were found for the 
analogues NPY l-4-Aca-24-36, NPY AC-1-4- 
Aca-25-36, NPY l-2-Aua-25-36 (Aua = 1 l-ami- 
noundecanoic acid). The binding constants were 
reduced in case of the analogues NPY 1-4- 
Aca-25-36 [Phe’], NPY l-(Aca)z-25-26 and NPY 
1 -4-Aca-25-36[Ala’-Pro’-Leu3-Glu4] containing 
the bovine pancreatic polypeptide segment l-4. 
Results of receptor binding and biological activity 
are summarized in table 1. 
In summary, based on the hypothetical 3D struc- 
ture of NPY, drastically shortened analogues con- 
sisting of N- and C-terminal segments of NPY 
have been modelled and synthesized. These 
Table 1 
Receptor binding affinity constants, postsynaptic and 
presynaptic activities of NPY and short synthetic analogues 
Peptides Receptor Post- Pre- 
binding synaptic synaptic 
(n%) 
activity activity 
EC30 IC50 
WWW WV 
NPY 0.05 0.12 
NPY 1-4-Aca-25-36 0.16 83 
NPY 1-4-Aca-24-36 0.6 17 
NPY AC-1-4-Aca-25-36 0.8 n.d. 
NPY 1-2-Aua-25-36 0.9 52 
NPY 1-4-Aca-25-36[Phe’] 4.8 70 
NPY 1-4-Aoa-25-36 5.6 460 
NPY l-Acaz-25-36 6.3 72 
NPY l-4-Aca-25-36[Ala’- 
Pro’-Leu’-Glu4] 10 460 
n.d., not determined 
19 
180 
180 
n.d. 
280 
160 
170 
160 
750 
analogues exhibited high receptor affinity and 
strong NPY agonistic properties. 
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